癌症惡病質市場規模、佔有率和成長分析（按產品類型、作用機制、分銷管道和地區）- 2025-2032 年產業預測

2023 年全球癌症惡病質市場規模價值 28.3 億美元，預計將從 2024 年的 29.6 億美元成長到 2032 年的 42.1 億美元，預測期內（2025-2032 年）的複合年成長率為 4.5%。

根據美國國家生物技術資訊中心的最新資料，惡病質影響約 80% 的晚期癌症患者，並導致全球 20% 的癌症相關死亡。這種消耗症候群的特徵是體重明顯下降、厭食、骨質疏鬆和貧血，在癌症、慢性阻塞性肺病和愛滋病毒等慢性疾病中普遍存在，每年在美國影響約 130 萬名癌症患者。由於高齡化社會特別容易受到癌症的侵害，開發針對癌症惡病質的治療方法具有巨大的市場機會。患者數量的增加凸顯了創新干預措施的必要性，進一步推動市場擴張並解決腫瘤學領域的關鍵患者照護挑戰。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 資料和主要資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管格局
• 專利分析

癌症惡病質市場規模（按產品類型和複合年成長率） (2025-2032)

• 市場概況
• 黃體素
• 皮質類固醇
• 聯合治療
• 其他

癌症惡病質市場規模（按作用機制和複合年成長率） (2025-2032)

• 市場概況
• 促進食慾
• 減重穩定劑

癌症惡病質市場規模（按分銷管道和複合年成長率） (2025-2032)

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局

癌症惡病質市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Merck & Co., Inc.（USA）
• Aphios Corporation（USA）
• Helsinn Group（Switzerland）
• Bristol-Myers Squibb Company（USA）
• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Novartis AG（Switzerland）
• Veru Inc.（USA）
• Mylan NV（USA）
• Hikma Pharmaceuticals PLC（UK）
• AbbVie Inc.（USA）
• Amgen Inc.（USA）
• AstraZeneca PLC（UK）
• Johnson & Johnson（USA）
• GlaxoSmithKline PLC（UK）
• F. Hoffmann-La Roche AG（Switzerland）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Takeda Pharmaceutical Company Limited（Japan）

結論和建議

Global Cancer Cachexia Market size was valued at USD 2.83 billion in 2023 and is poised to grow from USD 2.96 billion in 2024 to USD 4.21 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

Recent data from the National Center for Biotechnology Information indicates that cachexia affects around 80% of advanced cancer patients, contributing to 20% of cancer-related deaths worldwide. This wasting syndrome, characterized by significant weight loss, anorexia, osteoporosis, and anemia, is prevalent in chronic diseases like cancer, COPD, and HIV, impacting approximately 1.3 million cancer patients annually in the U.S. As the global cancer incidence continues to rise, so does the potential market for cachexia treatments. With the aging population particularly vulnerable to cancer, there is substantial market opportunity for developing therapies targeting cancer cachexia. The growing patient population emphasizes the need for innovative interventions, further propelling market expansion and addressing critical patient care challenges in the oncology space.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Cachexia market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Cachexia Market Segments Analysis

Global Cancer Cachexia Market is segmented by Product Type, Mechanism of Action, Distribution Channel and Region. Based on Product Type, the market is segmented into Progestogens, Corticosteroids, Combination Therapies and Others. Based on Mechanism of Action, the market is segmented into Appetite Stimulators and Weight Loss Stabilizers. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Cachexia Market

The global Cancer Cachexia market is primarily driven by the limited treatment options currently available for managing cachexia in cancer patients, which predominantly include progestogens and corticosteroids. While these medications have demonstrated some effectiveness, the variability in clinical outcomes highlights a significant unmet need, as there are no specific drug approvals tailored for this condition. This gap in therapeutic solutions presents an opportunity for market participants to engage in research and development efforts aimed at creating innovative treatments. As companies strive to address this deficiency, the global market is poised for growth through the introduction of novel drug candidates.

Restraints in the Global Cancer Cachexia Market

Although the global cancer cachexia market is witnessing a rise in prevalence, several challenges are hindering its expansion. These include the exorbitant costs linked to cancer and its adjunct treatments, along with inadequate drug reimbursement in developing nations. Treatment expenses for cancer patients suffering from cachexia are generally higher than those for non-cachexia patients, resulting in significant out-of-pocket expenses. Additionally, the scarcity of approved therapeutic options for this condition further hampers market growth. Consequently, these factors are likely to lead to a gradual increase in the market throughout the projected timeframe.

Market Trends of the Global Cancer Cachexia Market

The global cancer cachexia market is witnessing a notable trend towards the adoption of combination therapies, driven by the limitations of traditional single-drug approaches, which often yield insufficient therapeutic benefits. With a scarcity of approved drugs specifically for cancer cachexia, healthcare providers are increasingly embracing multicomponent strategies that integrate both pharmacological and non-pharmacological interventions. Clinical trials have demonstrated significant improvements in lean body mass (LBM) among patients receiving these combination therapies. As healthcare professionals advocate for these multifaceted treatment regimens, patient acceptance is rising, thereby fueling demand and expanding opportunities in the global cancer cachexia market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Cancer Cachexia Market Size by Product Type & CAGR (2025-2032)

• Market Overview
• Progestogens
• Corticosteroids
• Combination Therapies
• Others

Global Cancer Cachexia Market Size by Mechanism of Action & CAGR (2025-2032)

• Market Overview
• Appetite Stimulators
• Weight Loss Stabilizers

Global Cancer Cachexia Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Cancer Cachexia Market Size & CAGR (2025-2032)

• North America (Product Type, Mechanism of Action, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Mechanism of Action, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Mechanism of Action, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Mechanism of Action, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Mechanism of Action, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aphios Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helsinn Group (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veru Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations